- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Inovio Pharmaceuticals Faces Deadline in Investor Lawsuit
Rosen Law Firm encourages shareholders to act before final deadline in class action case.
Apr. 3, 2026 at 5:08am
Got story updates? Submit your updates here. ›
A ghostly X-ray image illuminates the complex inner workings of a COVID-19 vaccine, as a class action lawsuit alleges Inovio misled investors about its development.NYC TodayInovio Pharmaceuticals, a biotechnology company focused on developing DNA medicines and vaccines, is facing a final deadline for a class action lawsuit filed by investors. The Rosen Law Firm, a leading investor counsel, is urging Inovio shareholders to come forward and join the case before the cutoff date.
Why it matters
The lawsuit alleges that Inovio made misleading statements about the progress and timeline of its COVID-19 vaccine candidate, which impacted the company's stock price. The outcome of this case could have significant financial implications for Inovio and set precedents around transparency and accountability in the pharmaceutical industry.
The details
The class action lawsuit was filed on behalf of investors who purchased Inovio stock between March 2020 and August 2021. The Rosen Law Firm alleges that Inovio issued false and misleading statements about the development of its COVID-19 vaccine candidate, INO-4800, which led to artificially inflated stock prices. The firm is encouraging all affected Inovio shareholders to join the case before the final deadline.
- The class action lawsuit was filed in March 2022.
- The final deadline for Inovio shareholders to join the case is April 11, 2026.
The players
Rosen Law Firm
A leading investor counsel that has filed the class action lawsuit against Inovio Pharmaceuticals.
Inovio Pharmaceuticals
A biotechnology company focused on developing DNA medicines and vaccines, including a COVID-19 vaccine candidate.
What they’re saying
“We encourage Inovio investors to contact us to discuss the case and their potential recovery.”
— Laurence Rosen, Managing Partner, Rosen Law Firm
What’s next
The final deadline for Inovio shareholders to join the class action lawsuit is April 11, 2026.
The takeaway
This case highlights the importance of transparency and accountability in the pharmaceutical industry, especially during the development of critical medical products like COVID-19 vaccines. The outcome could set precedents that impact how biotech companies communicate with investors going forward.
